Substance / Medication

Teniposide

SNOMED 387460005 UMLS C0039512

Overview

Active Ingredient

teniposide

RxNorm CUI

10362

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Neoplasm of lung

Lymphatic leukaemia

Small cell carcinoma

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)

NCT00361140Phase 4Completed72 enrolled

ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)

NCT02670564Phase 4Recruiting1000 enrolled

View all 2 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

[Radiotherapy of malignant brain gliomas using teniposide].

Mufazalov F F, Sakaeva D D, Shtefan A Iu · Vopr Onkol · 2008

PMID: 18522171RCT

Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.

Bromberg Jacoline E C, Issa Samar, van der Holt Bronno et al. · Neuro Oncol · 2024

PMID: 38037691TrialFull text (PMC)

Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial.

Wu Jingjing, Duan Lingling, Zhang Lei et al. · J Neurooncol · 2018

PMID: 30109672TrialFull text (PMC)

Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer.

Khan Tanweera S, Sundin Anders, Juhlin Claes et al. · Med Oncol · 2004

PMID: 15299189Trial

[Chemotherapy with higher or lower dose of teniposide combined with cisplatin and pingyangmycin for oral squamous cell carcinoma].

Chen Wan-tao, Guo Wei, Xu Qin et al. · Zhonghua Kou Qiang Yi Xue Za Zhi · 2004

PMID: 15196390Trial

Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study.

Brandes A A, Basso U, Vastola F et al. · Ann Oncol · 2003

PMID: 14630676Trial

Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.

Weller Michael, Müller Bettina, Koch Rainer et al. · J Clin Oncol · 2003

PMID: 12947063Trial

Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588).

Ettinger David S, Finkelstein Dianne M, Ritch Paul S et al. · Lung Cancer · 2002

PMID: 12234701Trial

[Teniposide and cisplatin compared with etoposide and cisplatin for treatment of small cell lung cancer].

Fan Yun, Huang Zhi-yu, Zhang Yi-ping et al. · Ai Zheng · 2002

PMID: 12520751Trial

Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group.

Postmus P E, Haaxma-Reiche H, Smit E F et al. · J Clin Oncol · 2000

PMID: 11013281Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Teniposide (substance)
SNOMED CT: 387460005
UMLS CUI: C0039512
RxNorm CUI: 10362

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.